The Body on Defense
In his lab at Duke, Joel Collier uses synthetic nanomaterials to boost the body’s natural defenses
When a person gets sick, the invading virus or bacteria often triggers an immune response, sending a wave of white blood cells to attack the source of the illness. While the body’s natural defenses can often dismantle the infection, the immune reaction can sometimes cause more harm than intended.
That’s where Joel Collier’s lab comes in.
Collier, an associate professor in Duke University’s Department of Biomedical Engineering, creates biomaterials that can help understand and control adaptive immune responses. Most of the lab’s projects involve using biomaterials, peptides and proteins to devise immune therapies for a variety of diseases, ranging from cancer to Crohn’s disease.
“Figuring out how we can design these materials to self-assemble and appropriately interact with the immune system is a big challenge,” says Collier. “Every type of immunological cell that interacts with these materials does so in a different manner, so we have to build our materials in a way that stimulates the right combination of cells to behave the right way.”
One of the main foci within immune engineering is devising how to induce the immune system to combat diseases that lack highly protective vaccines, like HIV, malaria and influenza. To address this issue, Collier and his research group collaborate with the Duke Human Vaccine Institute to explore how they can use engineered nanomaterials to improve vaccines.
“Broadly neutralizing antibodies are one of the holy grails of vaccination, and the folks at the Duke Human Vaccine Institute have spent years refining their ideas and technologies for raising the best antibodies,” says Collier. “In collaboration with Genevieve Fouda, Sallie Permar, and Kevin Saunders, we are arraying these antigens on nanomaterials. HIV, for example, is very diverse, so you need antibodies that will neutralize as many strains as possible.”
“We were able to explore this topic using seed funding from MEDx and Duke’s Center for AIDS Research (CFAR),” says Chelsea Fries, one of the PhD students in the Collier lab leading this work. “Our group brings new nanomaterials to the table, providing technology that allows us to control how immune cells interact with HIV antigens. We hope that the unique architecture of our materials will promote stronger responses from B cells, which can make antibodies to fight diverse strains of HIV virus.”
Collier’s lab has also broadened their efforts to focus on non-infectious diseases like cancer. Collier and Yaoying Wu, a post-doctoral fellow in his lab, are working with John Sampson, MD, the Robert and Gloria Wilkins Professor of Neurosurgery in the Duke University School of Medicine, who studies glioblastoma, a deadly form of brain cancer. Using specific antigens identified by the Sampson lab, Collier and Wu are exploring how they can use a synthetic version of their platform to boost the activity of both B cells, which make antibodies, and T cells, which recognize and kill infected cells directly, to combat cancer.
In addition to these projects, the Collier lab has zeroed in on a relatively unexplored research topic: how to use the immune system to fight inflammatory diseases.
One of the hallmarks of inflammatory diseases is the overproduction of inflammatory signaling proteins known as cytokines. One of the most important inflammatory cytokines is a protein called TNF. Currently, deploying manufactured antibodies that target TNF is the best way to lower its levels. But this method requires patients to inject themselves regularly with the antibody, which is expensive, does not work for many patients, and can eventually stop working.
Instead, Collier and his team are investigating ways to use nanomaterials to induce the body’s immune system to become an anti-TNF antibody factory itself. But that is easier said than done, as patients would also need a way to regulate the amount of antibodies in their system.
“If our idea is successful, you would get an initial dose and then you’d be able to get a booster far less frequently,” says Collier. “The big challenge now is learning how to tune the antibody level up, down, or off. But if we can develop these strategies, we’ve got a whole new way of treating inflammatory disease, and that’s very exciting. We can also think about targeting other harmful proteins in the body, so the approach could ultimately have very broad applicability.”
According to Collier, these neglected frontiers in immunotherapy and immune engineering are among the most exciting aspect of his group’s research in Duke BME.
“Most immunotherapy research is focused on cancer and infectious diseases, but I also like to steer our group to places where few people are looking. I find that you can have a bigger impact if you can go places where others aren’t,” says Collier.
“We’re active in the more traditional and competitive areas of vaccine development, but often I think our biggest long-term potential involves our least traditional projects. And we’re putting ideas out there, right? We might get all the way there, we may get part of the way, but putting ideas out there allows the rest of the scientific community to also run with them.”